These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 25972546)

  • 1. Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.
    Cortez LM; Campeau J; Norman G; Kalayil M; Van der Merwe J; McKenzie D; Sim VL
    J Virol; 2015 Aug; 89(15):7660-72. PubMed ID: 25972546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.
    Norman G; Campeau J; Sim VL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bile acid TUDCA and neurodegenerative disorders: An overview.
    Zangerolamo L; Vettorazzi JF; Rosa LRO; Carneiro EM; Barbosa HCL
    Life Sci; 2021 May; 272():119252. PubMed ID: 33636170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-hydroxytamoxifen leads to PrPSc clearance by conveying both PrPC and PrPSc to lysosomes independently of autophagy.
    Marzo L; Marijanovic Z; Browman D; Chamoun Z; Caputo A; Zurzolo C
    J Cell Sci; 2013 Mar; 126(Pt 6):1345-54. PubMed ID: 23418355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation.
    Alleaume-Butaux A; Nicot S; Pietri M; Baudry A; Dakowski C; Tixador P; Ardila-Osorio H; Haeberlé AM; Bailly Y; Peyrin JM; Launay JM; Kellermann O; Schneider B
    PLoS Pathog; 2015 Aug; 11(8):e1005073. PubMed ID: 26241960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
    Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
    PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fundamentals of prion diseases and their involvement in the loss of function of cellular prion protein.
    Sakudo A; Ikuta K
    Protein Pept Lett; 2009; 16(3):217-29. PubMed ID: 19275734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
    Bate C; Tayebi M; Williams A
    BMC Biol; 2008 Feb; 6():8. PubMed ID: 18269734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion infection of differentiated neurospheres.
    Herva ME; Relaño-Ginés A; Villa A; Torres JM
    J Neurosci Methods; 2010 May; 188(2):270-5. PubMed ID: 20206206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function.
    Leighton PL; Allison WT
    J Alzheimers Dis; 2016 Jul; 54(1):3-29. PubMed ID: 27392869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An astrocyte cell line that differentially propagates murine prions.
    Tahir W; Abdulrahman B; Abdelaziz DH; Thapa S; Walia R; Schätzl HM
    J Biol Chem; 2020 Aug; 295(33):11572-11583. PubMed ID: 32561641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease.
    Ramalho RM; Viana RJ; Low WC; Steer CJ; Rodrigues CM
    Trends Mol Med; 2008 Feb; 14(2):54-62. PubMed ID: 18218342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases.
    Khalaf K; Tornese P; Cocco A; Albanese A
    Transl Neurodegener; 2022 Jun; 11(1):33. PubMed ID: 35659112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic aspects of prion diseases: an overview.
    Vranac T; Bresjanac M
    Curr Drug Targets; 2010 Oct; 11(10):1207-17. PubMed ID: 20840065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol-derived bile acids enhance the chaperone activity of α-crystallins.
    Song S; Liang JJ; Mulhern ML; Madson CJ; Shinohara T
    Cell Stress Chaperones; 2011 Sep; 16(5):475-80. PubMed ID: 21380614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells.
    Bate C; Tayebi M; Diomede L; Salmona M; Williams A
    BMC Biol; 2008 Sep; 6():39. PubMed ID: 18789130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice.
    Ali T; Hannaoui S; Nemani S; Tahir W; Zemlyankina I; Cherry P; Shim SY; Sim V; Schaetzl HM; Gilch S
    Acta Neuropathol Commun; 2021 Apr; 9(1):58. PubMed ID: 33795005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system.
    McKinnon C; Goold R; Andre R; Devoy A; Ortega Z; Moonga J; Linehan JM; Brandner S; Lucas JJ; Collinge J; Tabrizi SJ
    Acta Neuropathol; 2016 Mar; 131(3):411-25. PubMed ID: 26646779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A receptor for infectious and cellular prion protein.
    Martins VR
    Braz J Med Biol Res; 1999 Jul; 32(7):853-9. PubMed ID: 10454744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prion's elusive reason for being.
    Aguzzi A; Baumann F; Bremer J
    Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.